INTRODUCTION
============

Phototoxicity is an acute light-induced skin irritation when photoreactive chemicals are topically or systemically applied ([@b1-tr-33-043]). Phototoxicity begins when photoreactive chemicals are excited by absorption of ultraviolet and visible light (UV/VIS). The excited chemicals can then transfer the absorbed energy and generate reactive oxygen species (ROS). The increased ROS levels provoke cytotoxicity through damage of DNA, lipids and proteins by oxidative stress ([@b2-tr-33-043],[@b3-tr-33-043]). Several types of drugs, such as antibiotics, anticonvulsants, antimalarials, antipsychotics, thiazide diuretics, non-steroidal anti-inflammatory drugs and others, have phototoxic potential and can cause notable phototoxic reactions such as sunburn and hyperpigmentation ([@b4-tr-33-043]--[@b6-tr-33-043]). Because of drug-induced phototoxicity, regulatory agencies, US FDA, EU EMA and ICH, provide photosafety guidances, introducing test methods and evaluation strategies ([@b1-tr-33-043],[@b7-tr-33-043],[@b8-tr-33-043]). Following the ICH guidance S10, few non-animal testing methods for phototoxicity are recommended and these include measurement of the molar extinction coefficient (MEC), a standard ROS assay, a 3T3 neutral red uptake phototoxicity assay and a reconstructed human skin model assay.

The ROS assay was developed to screen photoreactivity of drugs through generation of the superoxide anion (type 1 reaction) and singlet oxygen (type 2 reaction) and their generation is an early stage chemical reaction as part of the phototoxicity mechanism ([@b6-tr-33-043]). The ROS assay protocol was established and the validation studies were conducted under the direction of the Japanese Center for the Validation of Alternative Methods (JaCVAM) ([@b9-tr-33-043]--[@b11-tr-33-043]). For the assay, high sensitivity and reproducibility were demonstrated and as part of the test, two solar simulators Suntest CPS series and SXL-2500V2 were evaluated. This assay, however, has low specificity, showing high false positive results. For this reason, we only focused on the effect of UVA (315\~400 nm), which is much important than other ultraviolet in phototoxicity. In addition, a UVA simulator is commonly used for phototoxicity evaluations. In this study, we evaluated the performance of the ROS assay with UVA (UVA ROS assay) instead of sunlight (290\~700 nm) using 50 phototoxins and 10 non-phototoxins.

MATERIALS AND METHODS
=====================

Chemicals and materials
-----------------------

Sixty test substances, including reference chemicals and phototoxic/non-phototoxic drugs, were selected for evaluation from the ROS assay protocol, a validation report of the ROS assay, package inserts and previous studies ([@b6-tr-33-043],[@b9-tr-33-043]--[@b16-tr-33-043]). 4-Aminobenzoic acid, 6-methylcoumarin, 8-methoxy psoralen, acridine, amiodarone, amlodipine, amoxapine, aspirin, atorvastatin, benzocaine, bezafibrate, bithionol, chlorothiazide, chlorpromazine HCl, ciprofloxacin, dapsone, demeclocycline, diclofenac, doxycycline, erythromycin, fenofibrate, flutamide, fluvastatin, furosemide, gliclazide, griseofulvin, hydrochlorothiazide, ibuprofen, ketoprofen, levofloxacin, losartan, lovastatin, methotrexate, nalidixic acid, naproxen, nifedipine, nitrofurantoin, norfloxacin, octyl salicylate, ofloxacin, omeprazole, oxytetracycline HCl, penicillin G, perphenazine, phenytoin, piroxicam, promethazine HCl, quinidine, quinine HCl, tetracycline, tiaprofenic acid, dimethyl sulfoxide (DMSO), sodium phosphate monobasic, sodium phosphate dibasic, p-nitroso-dimethylaniline (RNO), imidazole and nitroblue tetrazolium chloride (NBT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Enoxacin, lomefloxacin, meloxicam, mequitazine, nitrendipine, pitavastatin and rosiglitazone were obtained from Santa Cruz (Dallas, TX, USA). L-Histidine and sulisobenzone were purchased from Tokyo Chemical Industry (Tokyo, Japan). Quartz reaction containers were obtained from Ozawa Science (Aichi, Japan). Spectrophotometer cuvettes were purchased from Eppendorf (Hamburg, Germany). The 96-well plates (clear, flat-bottom, without lid) were obtained Corning (Corning, NY, USA). Following the ROS assay protocol, 20 mM sodium phosphate buffer (NaPB, pH 7.4), 0.2 mM p-Nitrosodimethylaniline (RNO), 20 mM imidazole and 0.4 mM nitroblue tetrazolium chloride (NBT) were prepared ([@b10-tr-33-043]). All test substances and reagents were protected from light.

UV spectral analysis
--------------------

UV spectral analysis was conducted as described in a previous study ([@b6-tr-33-043]). The test substances were dissolved in 20 mM sodium phosphate buffer (NaPB, pH 7.4) at 20 μM (final concentration). The UV/VIS absorption spectra were analyzed with a microplate spectrophotometer (Mecasys, Daejeon, Korea), and a spectrophotometer cuvette with a 10-mm pathlength was used. The MEC values were calculated using the highest absorption peaks from 290 to 700 nm.

Conditions of irradiation
-------------------------

A UVA simulator equipped with 40 W lamps was used (Vilbert-Lourmat, Marne-la-vallee, France). The UVA irradiation test was conducted at 25°C with 2.0 mW/cm^2^ irradiance measured by a UVA detector (UVP, Cambridge, UK).

Reactive oxygen species (ROS) assay
-----------------------------------

ROS assay was performed as previously described in Onoue et al. ([@b9-tr-33-043],[@b11-tr-33-043]) and the ROS assay protocol ([@b10-tr-33-043]). Stock solutions of all test substances were prepared at 10 mM in DMSO or 20 mM sodium phosphate buffer (NaPB, pH 7.4) and used within the same day for accurate data. To detect the generation of singlet oxygen and superoxide anion, all prepared test substance stock solutions were mixed in reagents, containing 400 μM NBT in 20 mM NaPB (pH 7.4) for singlet oxygen (SO) and 200 μM RNO and 50 μM imidazole in 20 mM NaPB (pH 7.4) for superoxide anion (SA) detection, and the final concentration of test substances in the reaction mixture was at 200 μM. When precipitation was observed using a microscope (×100 magnification) in the reaction mixture, appropriate final concentrations (20, 50, 100 μM) were used. Two hundred microliters of each reaction mixture were put into three wells of a 96-well plate. Before UVA exposure, absorbance was measured at 440 nm for SO and 560 nm for SA by a microplate spectrophotometer and then a quartz reaction container was installed in the plate. The plate was irradiated with a UVA simulator. After irradiation, the absorbance at 440 nm and 560 nm for the plate was measured. Following the ROS assay protocol, ROS generation of SO and SA was calculated by mean absorbance before and after irradiation.

Data judgment
-------------

Photoreactivity of the test substances was judged according to the following criteria ([@b10-tr-33-043],[@b11-tr-33-043]). A test substance was classified as a photoreactive substance when an SO value 25 or more and/or an SA value 20 or more was measured; in turn, it was judged to be a non-photoreactive substance when values of less than 25 for SO and less than 20 for SA were recorded.

RESULTS
=======

Optimization of the irradiance dose
-----------------------------------

To use a UVA simulator, we performed a preliminary study in order to find the appropriate UVA dose with the reference chemicals listed in the ROS assay protocol ([@b10-tr-33-043]). We exposed at 2.0 mW/cm^2^ irradiance, which is in the irradiance range of Atlas Suntest CPS/CPS+ in the ROS assay ([@b10-tr-33-043]). We irradiated at up to 18 J/cm^2^ at intervals of 3 J/cm^2^ and recorded the phototoxic information. The results produced at 9 or more J/cm^2^ were matched with their phototoxic potential ([Table 1](#t1-tr-33-043){ref-type="table"}). Also, values of positive and negative substances met the acceptance criteria ([@b17-tr-33-043],[@b18-tr-33-043]). Considering the results obtained with the irradiation times, we selected the UVA dose of 9 J/cm^2^ for the main study.

Results of ROS assay using UVA simulator
----------------------------------------

Using the selected UVA dose, we identified the performance of the ROS assay with 60 test substances including 50 phototoxins and 10 non-phototoxins ([Table 2](#t2-tr-33-043){ref-type="table"}). Firstly, we measured an MEC for all the test substances if they were photoreactive. Four substances, ibuprofen, erythromycin, penicillin G and phenytoin, had an MEC of less than 1,000. Next, we tested their solubility and identified precipitation, coloration or any other interference at 200 μM in the reaction mixture. Amiodarone, demeclocycline, fenofibrate, piroxicam and rosiglitazone showed precipitation in the reaction mixture for SO and/or SA and an appropriate concentration was further explored for them. Except for amiodarone, the substances with the solubility issues were dissolvable at least at 20 μM. As such, the evaluable test substances were determined be 59 of the original 60. The test results indicated that the UVA ROS assay correctly classified 42 of 49 phototoxins and 10 of 10 non-phototoxins. Amoxapine, atorvastatin, flutamide, griseofulvin, hydrochlorothiazide, nifedipine and nitrendipine were falsely judged as being non-phototoxins. The predictive capacity showed an 85.7% sensitivity, 100.0% specificity and 88.1% accuracy ([Table 3](#t3-tr-33-043){ref-type="table"}).

DISCUSSION
==========

To use a UVA simulator instead of validated solar simulators, we established the irradiation condition of the ROS assay with UVA. We chose a UVA irradiance of 2.0 mW/cm^2^, which has been used in Atlas Suntest CPS series and has shown the lowest variation in a previous study ([@b6-tr-33-043]). We found an appropriate UVA intensity that was compatible with phototoxic information of reference chemicals ([Table 1](#t1-tr-33-043){ref-type="table"}). Also, the selected intensity sufficiently generated ROS and in the range of 5\~20 J/cm^2^, which is widely used in *in vitro* and *in vivo* phototoxic assays ([@b1-tr-33-043]).

Solubility evaluation of test substance solutions proceeded right before the assay, in order to prevent interference, such as precipitation and coloration that might affect the test results. To overcome a solubility problem, the ROS assay was modified to use the micelle system using Tween 20 ([@b18-tr-33-043]). Thus, low solubility substances could be evaluated for their phototoxic potential by adapting the micellar system to the UVA ROS assay.

The study results showed that the 7 phototoxic substances, amoxapine, atorvastatin, flutamide, griseofulvin, hydrochlorothiazide, nifedipine and nitrendipine, were classified as non-phototoxins ([Table 2](#t2-tr-33-043){ref-type="table"}). These substances showed a UVA absorption and MEC of over 1,000 but did not generate ROS, either singlet oxygen or superoxide anion species. Moreover, irradiation of UVA at up to 18 J/cm^2^ did not generate ROS (data not shown). However, these substances were correctly classified in previous studies, which used a solar simulator ([@b6-tr-33-043],[@b18-tr-33-043]). Different results between a UVA simulator and a solar simulator could be related with UVB wavelength. UVB may be an essential factor to generate ROS of these chemicals, even they absorbed UVA wavelength. Therefore, misclassified chemicals may not generate ROS. On the other hand, the final concentration of a test chemical, 200 μM, could be limited to generate ROS in the UVA ROS assay system. If using more higher concentration than the final concentration, these chemicals would be generated ROS and met the criteria of photoreactivity. L-Histidine, penicillin G and phenytoin that were false positive substances in the ROS assay were correctly classified as non-phototoxins ([Table 2](#t2-tr-33-043){ref-type="table"}) ([@b6-tr-33-043],[@b9-tr-33-043],[@b11-tr-33-043]). Surprisingly, bezafibrate, gliclazide, ibuprofen and losartan generated superoxide anion and were thus classified as phototoxins even though they had low MEC values in the UV/VIS range (290\~700 nm). These results were consistent with those of the previous study, and MEC values cannot be always used to evaluate-phototoxic potential of chemicals ([@b6-tr-33-043]). We conducted the UVA ROS assay with 60 test substances to identify their phototoxic potential. The results showed that this assay could adequately evaluate phototoxicity of the test substances analyzed. In addition, the UVA ROS assay has higher specificity and lower sensitivity than the ROS assay, and the performance of the UVA ROS assay is comparable with that of the ROS assay ([Table 3](#t3-tr-33-043){ref-type="table"}). Our findings suggest that the UVA ROS assay could be used as a method for phototoxicity evaluation of pharmaceutical substances.
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###### 

Selection of UVA irradiation conditions using reference chemicals

  No.                          Substance name        CAS no.      Phototoxic information[\*](#tfn1-tr-33-043){ref-type="table-fn"}   Concentration (μM)   ROS assay (J/cm^2^)[\*\*](#tfn2-tr-33-043){ref-type="table-fn"}                                        
  ---------------------------- --------------------- ------------ ------------------------------------------------------------------ -------------------- ----------------------------------------------------------------- ----- ----- ---- ---- ---- ---- ---- ----
  Positive/negative controls                                                                                                                                                                                                                                     
  1                            Quinine HCl (PC)      6119-47-7    P                                                                  P                    P                                                                 200   200   \+   \+   \+   \+   \+   \+
  2                            Sulisobenzone (NC)    4065-45-6    N                                                                                       N                                                                 200   200   −    −    −    −    −    −
  Reference chemicals                                                                                                                                                                                                                                            
  3                            4-Aminobenzoic acid   150-13-0     N                                                                  N                                                                                      200   200   −    −    −    −    −    −
  4                            8-Methoxy psoralen    298-81-7     P                                                                  P                    P                                                                 200   200   −    −    \+   \+   \+   \+
  5                            Acridine              260-94-6     P                                                                  P                    P                                                                 200   200   \+   \+   \+   \+   \+   \+
  6                            Benzocaine            94-09-7      N                                                                                                                                                         200   200   −    −    −    −    −    −
  7                            Chlorpromazine        69-09-0      P                                                                  P                    P                                                                 200   200   −    \+   \+   \+   \+   \+
  8                            Diclofenac            15307-79-6                                                                                           P                                                                 200   200   \+   \+   \+   \+   \+   \+
  9                            Doxycycline           10592-13-9   P                                                                  P                    P                                                                 200   200   \+   \+   \+   \+   \+   \+
  10                           Erythromycin          114-07-8     N                                                                                                                                                         200   200   −    −    −    −    −    −
  11                           Fenofibrate           49562-28-9   P                                                                                       P                                                                 20    20    −    \+   \+   \+   \+   \+
  12                           Furosemide            54-31-9      P/N                                                                                     P                                                                 200   200   −    \+   \+   \+   \+   \+
  13                           L-Histidine           71-00-1      P                                                                                                                                                         200   200   −    −    −    −    −    −
  14                           Ketoprofen            22071-15-4   P                                                                  N                    P                                                                 200   200   \+   \+   \+   \+   \+   \+
  15                           Nalidixic acid        389-08-2     P                                                                  P                    P                                                                 200   200   \+   \+   \+   \+   \+   \+
  16                           Norfloxacin           70458-96-7   P                                                                  P                    P                                                                 200   200   \+   \+   \+   \+   \+   \+
  17                           Omeprazole            73590-58-6                                                                                           P                                                                 200   200   −    \+   \+   \+   \+   \+
  18                           Promethazine HCl      58-33-3      P                                                                                       P                                                                 200   200   \+   \+   \+   \+   \+   \+

Phototoxic information was from JaCVAM ([@b17-tr-33-043]) and Onoue *et al.* ([@b11-tr-33-043]); P, phototoxic; N, non-phototoxic.

+, Positive result; −, Negative result.

###### 

Results of the UVA ROS assay

  No.                              Substance name        CAS no.       UV absorption[\*](#tfn3-tr-33-043){ref-type="table-fn"}   Concentration (μM)   UVA ROS assay[\*\*](#tfn4-tr-33-043){ref-type="table-fn"}   Phototoxic information                                      
  -------------------------------- --------------------- ------------- --------------------------------------------------------- -------------------- ----------------------------------------------------------- ------------------------ -------------- -------------- ---- ----------------------------------------
  **Positive/negative controls**                                                                                                                                                                                                                                              
  1                                Quinine HCl (PC)      6119-47-7     331                                                       5250                 200                                                         200                      279.6 ± 24.5   190.3 ± 31.3   \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  2                                Sulisobenzone (NC)    4065-45-6     \(290\)                                                   9200                 200                                                         200                      0.6 ± 4.9      N.D.           −    ([@b11-tr-33-043])
  **Phototoxic substances**                                                                                                                                                                                                                                                   
  3                                6-Methylcoumarin      92-48-8       \(290\)                                                   8750                 200                                                         200                      39.4 ± 1.8     53.7 ± 4.5     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  4                                8-Methoxy psoralen    298-81-7      300                                                       12250                200                                                         200                      27.4 ± 7.3     18.6 ± 3.5     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  5                                Acridine              260-94-6      355                                                       9250                 200                                                         200                      169.1 ± 10.5   95.1 ± 4.0     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  6                                Amiodarone            19774-82-4    358/371                                                   10150                20                                                          20                       N.A.(P)        N.A.(P)        X    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  7                                Amlodipine            111470-99-6   365                                                       20900                200                                                         200                      9.9 ± 12.2     67.9 ± 34.0    \+   ([@b18-tr-33-043])
  8                                Amoxapine             14028-44-5    298                                                       9000                 200                                                         200                      N.D.           14.2 ± 10.3    −    ([@b6-tr-33-043])
  9                                Atorvastatin          134523-00-5   \(290\)                                                   9200                 200                                                         200                      13.1 ± 6.9     10.6 ± 7.3     −    ([@b18-tr-33-043])
  10                               Bezafibrate           41859-67-0    \(290\)                                                   345                  200                                                         200                      3.6 ± 3.4      24.8 ± 3.9     \+   ([@b18-tr-33-043])
  11                               Bithionol             97-18-7       322                                                       7750                 200                                                         200                      80.7 ± 7.2     21.1 ± 7.5     \+   ([@b11-tr-33-043])
  12                               Chlorothiazide        58-94-6       293                                                       11950                200                                                         200                      3.6 ± 1.2      38.6 ± 15.3    \+   ([@b6-tr-33-043])
  13                               Chlorpromazine HCl    69-09-0       293                                                       4600                 200                                                         200                      N.D.           55.0 ± 17.6    \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  14                               Ciprofloxacin         85721-33-1    322                                                       15300                200                                                         200                      198.3 ± 54.0   86.4 ± 12.2    \+   ([@b15-tr-33-043])
  15                               Demeclocyline         64-73-3       375                                                       15700                200                                                         50                       143.7 ± 12.8   46.1 ± 2.0     \+   ([@b12-tr-33-043])
  16                               Diclofenac            15307-79-6    \(290\)                                                   7850                 200                                                         200                      149.5 ± 10.3   150.8 ± 32.6   \+   ([@b6-tr-33-043])
  17                               Doxycycline           10592-13-9    348                                                       11650                200                                                         200                      67.2 ± 9.1     80.6 ± 4.0     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  18                               Enoxacin              74011-58-8    334                                                       13500                200                                                         200                      239.5 ± 5.1    357.6 ± 2.3    \+   ([@b18-tr-33-043])
  19                               Fenofibrate           49562-28-9    294                                                       11300                20                                                          20                       67.4 ± 15.8    N.D.           \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  20                               Flutamide             13311-84-7    291                                                       7800                 200                                                         200                      12.7 ± 4.1     7.3 ± 2.6      −    ([@b14-tr-33-043])
  21                               Fluvastatin           93957-55-2    303                                                       11050                200                                                         200                      190.4 ± 3.4    155.6 ± 12.6   \+   ([@b18-tr-33-043])
  22                               Furosemide            54-31-9       \(290\)                                                   2850                 200                                                         200                      74.3 ± 21.2    17.7 ± 8.6     \+   ([@b11-tr-33-043])
  23                               Gliclazide            21187-98-4    \-                                                        \-                   200                                                         200                      4.3 ± 10.2     91.7 ± 12.2    \+   ([@b18-tr-33-043])
  24                               Griseofulvin          126-07-8      295                                                       24200                200                                                         200                      4.4 ± 2.8      10.6 ± 2.9     −    ([@b18-tr-33-043])
  25                               Hydrochlorothiazide   58-93-5       318                                                       3350                 200                                                         200                      1.9 ± 3.3      N.D.           −    ([@b18-tr-33-043]), ([@b19-tr-33-043])
  26                               Ibuprofen             15687-27-1    294                                                       60                   200                                                         200                      1.8 ± 2.3      62.7 ± 10.7    \+   ([@b6-tr-33-043])
  27                               Ketoprofen            22071-15-4    \(290\)                                                   6450                 200                                                         200                      123.5 ± 12.8   76.4 ± 6.9     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  28                               Levofloxacin          138199-71-0   \(290\)                                                   27150                200                                                         200                      107.3 ± 28.6   367.3 ± 14.2   \+   ([@b18-tr-33-043])
  29                               Lomefloxacin          98079-52-8    326                                                       13350                200                                                         200                      693.9 ± 22.1   64.5 ± 1.5     \+   ([@b13-tr-33-043])
  30                               Losartan              124750-99-8   \(290\)                                                   925                  200                                                         200                      N.D.           50.3 ± 3.2     \+   ([@b18-tr-33-043])
  31                               Lovastatin            75330-75-5    325/333                                                   1950                 200                                                         200                      27.0 ± 8.9     N.D.           \+   ([@b18-tr-33-043])
  32                               Meloxicam             71125-38-7    \(290\)                                                   8350                 200                                                         200                      9.2 ± 1.9      31.9 ± 9.7     \+   ([@b18-tr-33-043])
  33                               Mequitazine           29216-28-2    303                                                       5850                 200                                                         200                      114.3 ± 11.9   15.4 ± 2.2     \+   ([@b18-tr-33-043])
  34                               Methotrexate          59-05-2       303                                                       26100                200                                                         200                      N.D.           195.1 ± 20.6   \+   Package insert
  35                               Nalidixic acid        389-08-2      335                                                       12100                200                                                         200                      73.2 ± 6.4     307.0 ± 16.8   \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  36                               Naproxen              22204-53-1    293                                                       3550                 200                                                         200                      39.6 ± 3.2     77.9 ± 8.2     \+   ([@b18-tr-33-043])
  37                               Nifedipine            21829-25-4    342                                                       5850                 200                                                         200                      8.8 ± 3.2      N.D.           −    ([@b6-tr-33-043])
  38                               Nitrendifine          39562-70-4    357                                                       5000                 200                                                         200                      N.D.           11.6 ± 1.5     −    ([@b6-tr-33-043])
  39                               Nitrofurantoin        67-20-9       381                                                       20800                200                                                         200                      62.4 ± 6.6     N.D.           \+   ([@b6-tr-33-043])
  40                               Norfloxacin           70458-96-7    323                                                       14450                200                                                         200                      167.3 ± 24.1   82.3 ± 34.6    \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  41                               Ofloxacin             82419-36-1    \(290\)                                                   28250                200                                                         200                      66.9 ± 6.4     349.6 ± 11.6   \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  42                               Omeprazole            73590-58-6    299                                                       14400                200                                                         200                      N.D.           92.0 ± 6.3     \+   ([@b6-tr-33-043])
  43                               Oxytetracycline HCl   2058-46-0     358                                                       16100                200                                                         200                      88.4 ± 25.0    66.8 ± 9.4     \+   ([@b6-tr-33-043])
  44                               Perphenazine          58-39-9       309                                                       3600                 200                                                         200                      N.D.           47.8 ± 9.5     \+   ([@b18-tr-33-043])
  45                               Piroxicam             36322-90-4    355                                                       17900                200                                                         50                       99.9 ± 5.8     37.2 ± 28.0    \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  46                               Pitavastatin          147526-32-7   291                                                       10900                200                                                         200                      N.A.(P)        47.9 ± 19.5    \+   ([@b18-tr-33-043])
  47                               Promethazine HCl      58-33-3       300                                                       3500                 200                                                         200                      59.5 ± 4.0     6.4 ± 4.5      \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  48                               Quinidine             56-54-2       331                                                       5200                 200                                                         200                      154.6 ± 14.9   87.6 ± 16.1    \+   ([@b19-tr-33-043])
  49                               Rosiglitazone         122320-73-4   311                                                       4900                 200                                                         20                       31.9 ± 5.9     10.1 ± 1.5     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  50                               Tetracycline          60-54-8       363                                                       15950                200                                                         200                      39.5 ± 5.4     49.0 ± 3.3     \+   ([@b11-tr-33-043]), ([@b17-tr-33-043])
  51                               Tiaprofenic acid      33005-95-7    316                                                       15500                200                                                         200                      654.5 ± 23.0   201.4 ± 15.4   \+   ([@b12-tr-33-043])
  **Non-phototoxic substances**                                                                                                                                                                                                                                               
  52                               4-Aminobenzoic acid   150-13-0      \(290\)                                                   7300                 200                                                         200                      −0.2 ± 0.8     −7.2 ± 0.5     −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  53                               Aspirin               50-78-2       \(290\)                                                   2050                 200                                                         200                      1.5 ± 2.8      N.D.           −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  54                               Benzocaine            94-09-7       \(290\)                                                   16850                200                                                         200                      N.D.           N.D.           −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  55                               Dapsone               80-08-0       294                                                       26250                200                                                         200                      10.7 ± 2.3     N.D.           −    ([@b19-tr-33-043])
  56                               Erythromycin          114-07-8      \-                                                        \-                   200                                                         200                      N.D.           15.1 ± 0.4     −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  57                               L-Histidine           71-00-1       291                                                       3000                 200                                                         200                      0.7 ± 0.6      6.3 ± 0.6      −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  58                               Octyl salicylate      118-60-5      \(290\)                                                   12500                20                                                          20                       3.5 ± 8.0      4.6 ± 3.8      −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  59                               Penicillin G          113-98-4      \-                                                        \-                   200                                                         200                      0.2 ± 0.3      9.8 ± 0.7      −    ([@b11-tr-33-043]), ([@b17-tr-33-043])
  60                               Phenytoin             57-41-0       295                                                       900                  200                                                         200                      N.D.           15.4 ± 0.9     −    ([@b11-tr-33-043]), ([@b17-tr-33-043])

When the maximum wavelengths were under 290 nm, these are marked 290 nm with parentheses.

SO: Singlet oxygen, SA: Superoxide anion, N.A. (P): Not available due to precipitation, N.D.: Not detected because SA or SO value was below zero.

###### 

Comparison of predictive capacity of the UVA ROS assay with the standard ROS assay using two solar simulators

                    Standard ROS assay[\*](#tfn5-tr-33-043){ref-type="table-fn"}   UVA ROS assay   
  ----------------- -------------------------------------------------------------- --------------- -------
  Sensitivity (%)   100.0                                                          100.0           85.7
  Specificity (%)   61.6                                                           55.9            100.0
  Accuracy (%)      86.8                                                           88.7            88.1

Performance capacity was from Onoue *et al*. ([@b11-tr-33-043]) and sensitivity, specificity and accuracy of each solar simulator in the ROS assay indicate the average of each participated lab results.

[^1]: These authors contributed equally to this study.
